Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

About Collegium Pharmaceutical

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company's lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The Company's DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing and/or dissolving, and then taking them orally or snorting or injecting them. It also focuses on development program for COL 195, an abuse deterrent, extended release hydrocodone for the treatment of chronic pain. It is focusing on COL 171, a preclinical DETERx extended release, abuse deterrent methylphenidate formulation for the treatment of ADHD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: COLL
  • CUSIP:
Key Metrics:
  • Previous Close: $14.04
  • 50 Day Moving Average: $15.51
  • 200 Day Moving Average: $14.92
  • 52-Week Range: $8.24 - $20.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.62
  • P/E Growth: 0.00
  • Market Cap: $329.38M
  • Outstanding Shares: 23,460,000
  • Beta: 0.25
Profitability:
  • Return on Equity: -80.20%
  • Return on Assets: -67.31%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.29%
  • Quick Ratio: 4.22%
Additional Links:
Companies Related to Collegium Pharmaceutical:

Analyst Ratings

Consensus Ratings for Collegium Pharmaceutical (NASDAQ:COLL) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.40 (80.91% upside)

Analysts' Ratings History for Collegium Pharmaceutical (NASDAQ:COLL)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016Jefferies Group LLCReiterated RatingBuy$27.00 -> $24.00View Rating Details
10/12/2016Piper Jaffray CompaniesSet Price TargetBuy$23.00View Rating Details
9/14/2016Needham & Company LLCReiterated RatingBuy$30.00View Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00View Rating Details
3/15/2016Janney Montgomery ScottInitiated CoverageBuy$25.00View Rating Details
2/19/2016William BlairInitiated CoverageOutperform$35.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
8/10/2016Q2($0.76)($1.05)ViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.29)($0.45)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Collegium Pharmaceutical (NASDAQ:COLL)
Current Year EPS Consensus Estimate: $-3.95 EPS
Next Year EPS Consensus Estimate: $-3.04 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.60)($0.42)($0.51)
Q2 20162($0.74)($0.45)($0.60)
Q3 20162($1.14)($0.85)($1.00)
Q4 20162($1.17)($0.86)($1.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Collegium Pharmaceutical (NASDAQ:COLL)
Insider Ownership Percentage: 37.93%
Institutional Ownership Percentage: 56.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.25View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Collegium Pharmaceutical (NASDAQ:COLL)
DateHeadline
News IconGlobal Allergy Treatment Market Set for Rapid Growth And Trend, by 2026 (NASDAQ:COLL)
www.medgadget.com - February 23 at 4:24 PM
News IconLongitude Capital Promotes Josh Richardson, M.D., To Managing Director (NASDAQ:COLL)
www.bio-medicine.org - February 17 at 5:47 PM
News IconIs The Sell-Side Predicting That Collegium Pharmaceutical Inc (NASDAQ:COLL) Will Move Higher? - Winfield Review (NASDAQ:COLL)
winfieldreview.com - February 16 at 11:36 AM
realistinvestor.com logoCollegium Pharmaceutical Inc (NASDAQ:COLL) EPS Projection At $0.21 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - February 15 at 3:18 AM
openpr.com logoAllergy Treatment Market size and Key Trends in terms of volume and value 2016-2026 (NASDAQ:COLL)
www.openpr.com - February 14 at 3:08 AM
News IconPrice Target Of Collegium Pharmaceutical Inc (NASDAQ:COLL)At $25.8 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - February 13 at 5:07 PM
sbwire.com logoMusculoskeletal Pains Market - Detailed Study Analysis and Forecast by 2025 (NASDAQ:COLL)
www.sbwire.com - February 10 at 4:44 PM
News IconCollegium Pharmaceutical Inc (NASDAQ:COLL) Mean Price Target At $25.8 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - February 9 at 2:51 AM
openpr.com logoMusculoskeletal Pains Market : The report segregates the market based on type, components, applications and geography (NASDAQ:COLL)
www.openpr.com - February 8 at 4:48 PM
realistinvestor.com logoCollegium Pharmaceutical Inc (NASDAQ:COLL) Is Expected To Post ... - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - February 8 at 3:33 AM
News IconCollegium Pharmaceutical Inc (NASDAQ:COLL) Target Price At $25.8 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - February 5 at 2:47 AM
News IconEPS Target Of Collegium Pharmaceutical Inc (NASDAQ:COLL)Set ... - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - February 2 at 4:46 PM
streetinsider.com logoCollegium Pharma (COLL) Reports Positive Topline Results of Trial Evaluating the Oral Abuse of Xtampza ER - StreetInsider.com (NASDAQ:COLL)
www.streetinsider.com - February 2 at 4:46 PM
streetinsider.com logoCollegium Pharma (COLL) Reports Positive Topline Results of Trial Evaluating the Oral Abuse of Xtampza ER (NASDAQ:COLL)
www.streetinsider.com - February 1 at 9:47 PM
capitalcube.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : February 1, 2017 (NASDAQ:COLL)
www.capitalcube.com - February 1 at 4:44 PM
finance.yahoo.com logoCollegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER (NASDAQ:COLL)
finance.yahoo.com - February 1 at 4:44 PM
finance.yahoo.com logo8:21 am Collegium Pharmaceutical announces 'positive' topline results from a trial evaluating the abuse potential and pharmacokinetics of oral administration of Xtampza ER compared to chewed Xtampza (NASDAQ:COLL)
finance.yahoo.com - February 1 at 4:44 PM
News IconCan This Stock Gain Traction: Collegium Pharmaceutical, Inc ... - Prospect Journal (NASDAQ:COLL)
prospectjournal.com - January 31 at 3:22 AM
News IconMarket Review: Indicator Watch for Collegium Pharmaceutical Inc (COLL) - Market Point (NASDAQ:COLL)
mtptnews.com - January 30 at 10:20 PM
News IconCollegium Pharmaceutical Inc (NASDAQ:COLL) Price Target Set At $25.8 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - January 30 at 10:20 PM
News IconEarnings in Full Force, Analysts Take Aim at Collegium Pharmaceutical Inc (NASDAQ:COLL) - Wall Street Beacon (NASDAQ:COLL)
wsbeacon.com - January 29 at 2:41 AM
News IconEPS Forecast Of Collegium Pharmaceutical Inc (NASDAQ:COLL) Set At $0.21 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - January 29 at 2:41 AM
realistinvestor.com logoEPS Projection Of Collegium Pharmaceutical Inc (NASDAQ:COLL) At $0.21 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - January 25 at 5:33 PM
News IconWill The Needle Move For Collegium Pharmaceutical Inc (NASDAQ:COLL) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:COLL)
wsbeacon.com - January 21 at 9:29 PM
News IconAllergy Treatment Market Volume Forecast and Value Chain Analysis 2016-2026 (NASDAQ:COLL)
reports.pr-inside.com - January 19 at 5:39 PM
News IconCollegium Pharmaceutical Inc COLL Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:COLL)
www.bioportfolio.com - January 19 at 5:39 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Collegium Pharmaceutical Inc (NASDAQ:COLL) - Wall Street Beacon (NASDAQ:COLL)
wsbeacon.com - January 19 at 2:47 AM
News IconLooking Ahead for Collegium Pharmaceutical Inc (NASDAQ:COLL); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:COLL)
aikenadvocate.com - January 17 at 10:17 PM
News IconStock Momentum Skidding to a Halt For Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Wall Street Beacon (NASDAQ:COLL)
wsbeacon.com - January 17 at 10:17 PM
capitalcube.com logoETFs with exposure to Collegium Pharmaceutical, Inc. : January 17, 2017 (NASDAQ:COLL)
www.capitalcube.com - January 17 at 5:16 PM
News IconStock ABR Collegium Pharmaceutical Inc (NASDAQ:COLL) At 1 - Stock Observer (NASDAQ:COLL)
www.thestockobserver.com - January 16 at 10:27 AM
capitalcube.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : January 16, 2017 (NASDAQ:COLL)
www.capitalcube.com - January 16 at 10:27 AM
News IconStock Reaching Most Volatile List Today: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Wall Street Beacon (NASDAQ:COLL)
wsbeacon.com - January 11 at 9:55 PM
News IconCollegium Pharmaceutical Inc (NASDAQ:COLL) EPS Estimated At $0.21 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - January 7 at 9:57 PM
News IconProjected EPS Of Collegium Pharmaceutical Inc (NASDAQ:COLL) At $-1.08 - Stock Observer (NASDAQ:COLL)
www.thestockobserver.com - January 7 at 4:56 PM
capitalcube.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : January 5, 2017 (NASDAQ:COLL)
www.capitalcube.com - January 5 at 4:59 PM
realistinvestor.com logoCollegium Pharmaceutical Inc (NASDAQ:COLL) Is Expected To Post EPS Of $0.21 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - January 4 at 2:54 AM
News IconLong-Term Growth Estimate Of Collegium Pharmaceutical Inc (NASDAQ:COLL) At $20 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - January 3 at 4:53 PM
News IconMean Price Target Of Collegium Pharmaceutical Inc (NASDAQ:COLL) At $25.8 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - December 28 at 4:27 PM
realistinvestor.com logoCollegium Pharmaceutical Inc (NASDAQ:COLL) EPS Estimaged At $0.21 - RealistInvestor.com (NASDAQ:COLL)
www.realistinvestor.com - December 28 at 12:11 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Prospect Journal (NASDAQ:COLL)
prospectjournal.com - December 27 at 12:12 PM
News IconCollegium Pharmaceutical Inc (NASDAQ:COLL) EPS Estimate At ... - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - December 26 at 11:47 AM
capitalcube.com logoCollegium Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : COLL-US : December 26, 2016 (NASDAQ:COLL)
www.capitalcube.com - December 26 at 11:47 AM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Prospect Journal (NASDAQ:COLL)
prospectjournal.com - December 20 at 8:50 AM
News IconVC Score In Focus for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Marion Business Daily (NASDAQ:COLL)
marionbusinessdaily.com - December 20 at 8:50 AM
capitalcube.com logoCollegium Pharmaceutical, Inc. – Value Analysis (NASDAQ:COLL) : December 19, 2016 (NASDAQ:COLL)
www.capitalcube.com - December 20 at 8:50 AM
News IconFollowing the Numbers on Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Marion Business Daily (NASDAQ:COLL)
marionbusinessdaily.com - December 18 at 4:30 PM
4-traders.com logoCollegium Pharmaceutical : The q3 2016 Earnings Estimate for Collegium Pharmaceutical Inc. Issued by William Blair (NASDAQ:COLL)
www.4-traders.com - December 17 at 9:39 PM
News IconEPS Forecast Of Collegium Pharmaceutical Inc (NASDAQ:COLL) At $0.21 - Transcript Daily (NASDAQ:COLL)
transcriptdaily.com - December 17 at 4:38 PM
4-traders.com logoCollegium Pharmaceutical : Announces the Addition of Xtampza ER to Express Scripts Formulary (NASDAQ:COLL)
www.4-traders.com - December 16 at 4:48 PM

Social

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2017?

5 analysts have issued 1 year target prices for Collegium Pharmaceutical's stock. Their forecasts range from $23.00 to $30.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $25.40 in the next year.

When will Collegium Pharmaceutical announce their earnings?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.86%), Frazier Management LLC (8.04%), Franklin Resources Inc. (7.66%), FMR LLC (3.90%), Highland Capital Management LP (2.92%) and State Street Corp (1.23%). Company insiders that own Collegium Pharmaceutical stock include John A Fallon, John Gordon Freund and Longitude Capital Partners, Ll.

Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Highland Capital Management LP, Perceptive Advisors LLC, FMR LLC, J. Goldman & Co LP, State Street Corp and Eventide Asset Management LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon, John Gordon Freund and Longitude Capital Partners, Ll.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Collegium Pharmaceutical stock cost?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $14.04.

Collegium Pharmaceutical (NASDAQ:COLL) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Earnings History Chart

Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Dividend History Chart

Dividend Payments by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Last Updated on 2/24/2017 by MarketBeat.com Staff